Alumis has revealed its plan to raise ~USD 300 million from an initial public offering (IPO) by issuing 17.65 million shares, with a target price between USD 16 and USD 18 per share. Foresite Capital Management, Baker Brothers Life Sciences LP, and AyurMaya Capital Management Fund LP are listed as principal shareholders of the IPO. After the IPO, Alumis plans to begin trading on Nasdaq under the ticker symbol, "ALMS."
The company expects to use the funds to support the Phase III psoriasis clinical trials of its lead candidate allosteric tyrosine kinase 2 (TYK2) inhibitor called "ESK-001" and to complete ongoing Phase II trials in a type of eye inflammation called "uveitis," as well as in systemic lupus erythematosus.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.